Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

Article

关键词: LEFT-VENTRICULAR DYSFUNCTION;    GLUCAGON-LIKE PEPTIDE-1;    CARDIAC-RESYNCHRONIZATION THERAPY;    QUALITY-OF-LIFE;    IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;    DIPEPTIDYL PEPTIDASE-4 INHIBITORS;    MILD PATIENTS HOSPITALIZATION;    CONVERTING ENZYME-INHIBITORS;    PRESERVED EJECTION FRACTION;    ASSIST DEVICE IMPLANTATION;   

DOI  :  10.1161/CIR.0000000000000691

来源: SCIE

【 摘 要 】

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.

【 授权许可】

Free